PT95202A - Processo para a preparacao de n-substituidas-4-pirimidinaminas e de composicoes farmaceuticas que os contem - Google Patents

Processo para a preparacao de n-substituidas-4-pirimidinaminas e de composicoes farmaceuticas que os contem

Info

Publication number
PT95202A
PT95202A PT95202A PT9520290A PT95202A PT 95202 A PT95202 A PT 95202A PT 95202 A PT95202 A PT 95202A PT 9520290 A PT9520290 A PT 9520290A PT 95202 A PT95202 A PT 95202A
Authority
PT
Portugal
Prior art keywords
loweralkyl
hydrogen
aryl
pyrimidinamins
substitutes
Prior art date
Application number
PT95202A
Other languages
English (en)
Other versions
PT95202B (pt
Inventor
Richard Charles Effland
Joseph Thomas Klein
Larry Davis
Gordon Edward Olsew
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of PT95202A publication Critical patent/PT95202A/pt
Publication of PT95202B publication Critical patent/PT95202B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
PT95202A 1989-09-05 1990-09-04 Processo para a preparacao de n-substituidas-4-pirimidinaminas e de composicoes farmaceuticas que os contem PT95202B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/402,415 US4983608A (en) 1989-09-05 1989-09-05 N-substituted-4-pyrimidinamines and pyrimidinediamines

Publications (2)

Publication Number Publication Date
PT95202A true PT95202A (pt) 1991-05-22
PT95202B PT95202B (pt) 1997-06-30

Family

ID=23591798

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95202A PT95202B (pt) 1989-09-05 1990-09-04 Processo para a preparacao de n-substituidas-4-pirimidinaminas e de composicoes farmaceuticas que os contem

Country Status (18)

Country Link
US (1) US4983608A (pt)
EP (1) EP0417584B1 (pt)
JP (1) JPH07116181B2 (pt)
KR (1) KR0162641B1 (pt)
AT (1) ATE163012T1 (pt)
AU (1) AU626450B2 (pt)
CA (1) CA2024572C (pt)
DE (1) DE69032020T2 (pt)
DK (1) DK0417584T3 (pt)
ES (1) ES2112830T3 (pt)
FI (1) FI904327A7 (pt)
GR (1) GR3026318T3 (pt)
IE (1) IE903213A1 (pt)
IL (1) IL95568A (pt)
NO (1) NO903851L (pt)
NZ (1) NZ235145A (pt)
PT (1) PT95202B (pt)
ZA (1) ZA907033B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5319096A (en) * 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
AU726058B2 (en) * 1995-09-01 2000-10-26 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
AU5438299A (en) * 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
US6410726B1 (en) 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
KR20030024659A (ko) * 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003076434A1 (en) * 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP2316459B1 (en) 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
IL166241A0 (en) * 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
SI1625121T1 (sl) * 2002-12-20 2010-04-30 Pfizer Prod Inc Derivati pirimidina za zdravljenje abnormalne rasti celic
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
ES2421139T3 (es) * 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
MXPA06013164A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US20060058525A1 (en) * 2004-09-01 2006-03-16 Rajinder Singh Synthesis of 2,4-pyrimidinediamine compounds
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20090099160A1 (en) * 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド Jakキナーゼインヒビターおよびそれらの使用
BRPI0614502A2 (pt) * 2005-07-30 2011-03-29 Astrazeneca Ab Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto
AU2006296386A1 (en) * 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
AU2008238379A1 (en) 2007-04-13 2008-10-23 Sanofi-Aventis A transition metal catalyzed synthesis of N-aminoindoles
GB2553716B (en) * 2015-04-17 2020-06-17 Univ Holy Ghost Duquesne Pyrrolopyrimidines as antitumor agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792562A (en) * 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
US4752610A (en) * 1985-12-04 1988-06-21 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing properties
DE3852335T2 (de) * 1987-04-24 1995-05-11 Hoechst Roussel Pharma N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
US4806554A (en) * 1988-01-11 1989-02-21 Hoechst-Roussel Pharmaceuticals, Inc. Pyrazol and indazolpyridinamines
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines

Also Published As

Publication number Publication date
KR0162641B1 (ko) 1998-12-01
US4983608A (en) 1991-01-08
FI904327A0 (fi) 1990-09-03
JPH07116181B2 (ja) 1995-12-13
NO903851D0 (no) 1990-09-04
DE69032020D1 (de) 1998-03-12
AU626450B2 (en) 1992-07-30
PT95202B (pt) 1997-06-30
EP0417584A2 (en) 1991-03-20
FI904327A7 (fi) 1991-03-06
ATE163012T1 (de) 1998-02-15
IL95568A (en) 1995-01-24
CA2024572C (en) 2000-09-26
JPH0393784A (ja) 1991-04-18
NZ235145A (en) 1992-12-23
GR3026318T3 (en) 1998-06-30
EP0417584A3 (en) 1992-02-26
DE69032020T2 (de) 1998-07-09
NO903851L (no) 1991-03-06
CA2024572A1 (en) 1991-03-06
EP0417584B1 (en) 1998-02-04
IE903213A1 (en) 1991-03-13
KR910006277A (ko) 1991-04-29
AU6208990A (en) 1991-03-14
ES2112830T3 (es) 1998-04-16
DK0417584T3 (da) 1998-09-23
IL95568A0 (en) 1991-06-30
ZA907033B (en) 1991-06-26

Similar Documents

Publication Publication Date Title
FI904327A0 (fi) N-substituerad-4-pyrimidinaminer och -pyrimidindiaminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
PT916646E (pt) Processo para a preparacao de um 2,5-diamino-3-hidroxi-hexano substituido
PT91931A (pt) Processo de preparacao de derivados de acido fenilalcanoico e de composicoes farmaceuticas que os contem
PT96145A (pt) Processo para a preparacao de novos derivados de aminoacidos e de composicoes farmaceuticas que os contem
PT89020A (pt) Processo para a preparacao de 3-(4(1-substituidas-4-piperazinil)butil)-4-tiazolidinonas e de composicoes farmaceuticas que as contem
PT94297A (pt) Processo para a preparacao de n-hetero-aril-purin-6-aminas e de composicoes farmaceuticas que as contem
PT94879A (pt) Processo para a preparacao de 1,3-di-hidro-1-(piridinilamino)-2h-indol-2-onas e de composicoes farmaceutics que os contem
PT96030A (pt) Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem
HU9200321D0 (en) Process for the production of n-(aryl-oxi-alkyl)-heteroaryl-8-azabicyclo(3.2.1)-octanes and medical preparations containing them
PT94878A (pt) Processo para a preparacao de 1-(piridinilamino)-2-pirrolidinonas e de composicoes farmaceuticas que os contem
SE8802412D0 (sv) Thiourea derivatives
PT94880A (pt) Processo para a preparacao de 2,3-di-hidro-1-(piridinil-amino)-indos e de composicoes farmaceuticas que os contem
PT98911A (pt) Processo para a preparacao de 3-(1h-indazol-3-il)-4-piridinaminas, seus intermediarios e composicoes farmaceuticas que os contem
PT82550B (pt) Processo de preparacao de derivados de 1,3-oxatiano e de composicoes farmaceuticas que os contem
PT97762A (pt) Processo para a preparacao de pirido {3,4-b} pirrolo-{1,2-e} {1,4,5} oxadiazepinas e de analogos relacionados e de composicoes farmaeuticas que os contem
PT94298A (pt) Processo para a preparacao de derivados de 4, 5, 5a, 6-tetra-hidro-3h-isoxazolo{5,4,3-k1}acridinas e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19901220

FG3A Patent granted, date of granting

Effective date: 19970312

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20120312